Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review

Year: 2023

Publisher: Inflammatory Bowel Diseases

Abstract: Ulcerative colitis (UC) is a chronic disease characterized by inflammation of the colon with a recurrent/remitting course. Clinical manifestations vary according to the extent of the disease and symptoms. Ustekinumab is a fully human IgG1κ anti-interleukin (IL)-12/23 monoclonal antibody currently approved for the treatment of moderate to severe active ulcerative colitis in adult patients who have had an inadequate response, have loss of response, or are intolerant to conventional therapy or a biologic drug or have medical contraindications to those treatments.

The aim of this study was to evaluate the efficacy, effectiveness and safety of ustekinumab as a treatment for ulcerative colitis in adult patients. To this end, it carried out a systematic review of the efficacy, effectiveness and safety of ustekinumab in ulcerative colitis. The search was conducted through PubMed, Embase and the Cochrane library. Two reviewers independently assessed study quality and extracted study data.

This systematic review concluded that for the treatment of ulcerative colitis, ustekinumab has not only demonstrated efficacy in randomized controlled trials (and their extension studies), but also effectiveness and safety in observational studies in actual clinical practice.

Keywords: ulcerative colitis , ustekinumab , efficacy , effectiveness , safety.

How to cite: Javier P Gisbert, PhD, Elizabeth Parody-Rúa, PhD, María Chaparro, PhD, Efficacy, Effectiveness, and Safety of Ustekinumab for the Treatment of Ulcerative Colitis: A Systematic Review, Inflammatory Bowel Diseases, 2023;, izac275, https://doi.org/10.1093/ibd/izac275